Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. (2020)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1182/bloodadvances.2020003314
PubMed Identifier: 33232476
Publication URI: http://europepmc.org/abstract/MED/33232476
Type: Journal Article/Review
Volume: 4
Parent Publication: Blood advances
Issue: 22
ISSN: 2473-9529